SUBSCRIBE
SUBSCRIBE
News   Policy

RepRegen™ Ltd. (Formerly Known as BioCeramic Therapeutics) Seeks US FDA 510(k) Clearance for StronBone(TM)

February 9, 2011 | 
1 min read
LONDON--(BUSINESS WIRE)--RepRegen, the ‘smart biomaterials’ company, announced today that RepRegen Inc. in the US has submitted StronBone to the U.S. FDA for 510(k) clearance.
Regulatory Europe
MORE ON THIS TOPIC
Insights
Stability, speed and strategy: Inside Australia’s early‑stage edge
October 29, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Contemporary art collage. Motivated, confident team go over light background with abstract object, red arrows. Concept of business development, teamwork, startup, finance, career.
Job Trends
Biopharma cuts at manufacturing plants expected to affect 4,000+
October 29, 2026
 · 
5 min read
 · 
Angela Gabriel
Staying ahead of your competitors. Accelerated development of the company. Innovation vision. Customized solution. Unique skills. Red paper plane and whites. 3d render
FDA
New FDA draft guidance doubles down on expediting approvals of personalized gene therapies
October 28, 2026
 · 
4 min read
 · 
Heather McKenzie
3d pharmaceutical world icon with included clipping path.
Opinion
Biotechs going to market alone must learn to go global
October 28, 2026
 · 
3 min read
 · 
Paul Bridges